HIGHLIGHTS
- who: Tingting Liu and colleagues from the Editor:, Osmania University, Jinan, China have published the research work: Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis, in the Journal: PLOS ONE of 24/09/2022
- what: The funders of this work had no role in study design data collection and analysis decision to publish or preparation of the manuscript. median rank of the best regimens and followed by Atezolizumab+BEV based CIT; while for OS in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.